MedTrace Logo

Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes

NCT04239586 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-01-27

No results posted yet for this study

Summary

The purpose of this study is to switch from insulin to oral sulfonylurea in patients with apparent type 1 diabetes or maturity onset diabetes in the young that are insulin treated. The molecular cause will be DNA variants in the HNF1A, HNF4A, or HNF1B genes that are of unknown significance (VUS, class 3) or known to be pathogenic (class 4 and 5).

Conditions

  • Maturity-Onset Diabetes of the Young, Type 3
  • Maturity Onset Diabetes of the Young, Type 1
  • Childhood Diabetes Mellitus
  • Insulin-dependent Diabetes Mellitus

Interventions

DRUG

Sulfonylurea

Starting treatment with sulfonylurea class of drug

Sponsors & Collaborators

  • Haukeland University Hospital

    lead OTHER

Principal Investigators

  • Pål R. Njølstad, MD, PhD · Haukeland University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-18
Primary Completion
2022-04-30
Completion
2022-04-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04239586 on ClinicalTrials.gov